Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.

#BioCryst has agreed to sell its European business based on #hereditaryangioedema therapy Orladeyo to Italy's #NeopharmedGentili in a #deal valued at $250 million upfront.

pharmaphorum.com/news/neophar...